Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid TumorsGlobeNewsWire · 3 days ago
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business DevelopmentGlobeNewsWire · Sep 29, 2026
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head AnalysisDefense World · Aug 29, 2026
Why is Sutro Biopharma Stock Falling On Wednesday?Benzinga · Aug 12, 2026
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 StudyGlobeNewsWire · Aug 12, 2026
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More247 Wallst · Aug 7, 2026Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$2.19 | -$2.33 | Miss |
| May 14, 2026 | -$2.32 | -$2.94 | Miss |
| Mar 23, 2026 | -$8.16 | -$5.29 | Beat |
| Nov 6, 2025 | -$3.94 | -$6.70 | Miss |
| Aug 7, 2025 | -$3.82 | -$1.40 | Beat |
| May 8, 2025 | -$6.30 | -$9.10 | Miss |